[1]黄飞翔,向廷秀,任国胜.驱动蛋白KIF18B对ER+乳腺癌细胞增殖、凋亡的影响及其临床意义[J].第三军医大学学报,2019,41(18):1738-1743.
 HUANG Feixiang,XIANG Tingxiu,REN Guosheng.High expression of kinesin KIF18B in estrogen receptor-positive breast cancer enhances cell proliferation and apoptosis resistance and predicts poor prognosis[J].J Third Mil Med Univ,2019,41(18):1738-1743.
点击复制

驱动蛋白KIF18B对ER+乳腺癌细胞增殖、凋亡的影响及其临床意义(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第18期
页码:
1738-1743
栏目:
基础医学
出版日期:
2019-09-30

文章信息/Info

Title:
High expression of kinesin KIF18B in estrogen receptor-positive breast cancer enhances cell proliferation and apoptosis resistance and predicts poor prognosis
作者:
黄飞翔向廷秀任国胜
重庆医科大学附属第一医院分子肿瘤与表观遗传学重庆市重点实验室,内分泌乳腺外科
Author(s):
HUANG Feixiang XIANG Tingxiu REN Guosheng

Department of Endocriology and Breast Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China

关键词:
KIF18B乳腺癌细胞增殖细胞凋亡
Keywords:
KIF18B breast cancer cell proliferation cell apoptosis
分类号:
R341; R730.23; R737.9
文献标志码:
A
摘要:

目的 探讨驱动蛋白KIF18B在雌激素受体阳性(estrogen receptor positive, ER+)乳腺癌细胞中的表达,其对增殖、凋亡等细胞生物学功能的影响及对ER+乳腺癌患者预后的意义。方法 RT-qPCR检测KIF18B在ER+乳腺癌细胞及乳腺癌组织中的表达,通过siRNA转染干扰KIF18B表达,Western blot检测干扰效果,采用CCK-8实验检测乳腺癌细胞的增殖,流式细胞术检测乳腺癌细胞的凋亡。通过Kaplan-Meier数据库分析不同KIF18B的表达水平对ER+乳腺癌患者预后的意义。结果 驱动蛋白KIF18B在ER+恶性乳腺癌细胞株和ER+乳腺癌组织中高表达,siRNA转染后乳腺癌细胞增殖能力减弱,凋亡增加,差异均有统计学意义(P<0.05)。Kaplan-Meier分析显示,KIF18B高表达组的ER+乳腺癌患者OS、RFS较低表达组明显降低(P<0.05);在ER+并接受他莫昔芬治疗的乳腺癌患者中,KIF18B高表达组DMFS和RFS较低表达组明显降低(P<0.05)。结论 驱动蛋白KIF18B在ER+乳腺癌中高表达,并促进ER+乳腺癌细胞的增殖和抗凋亡能力,高表达KIF18B的ER+乳腺癌患者预后较差。

Abstract:

Objective To investigate the expression of kinesin KIF18B in breast cancer cells and its impact on the cell proliferation, apoptosis, and prognosis of estrogen receptor-positive(ER+) breast cancer. MethodsThe expression of KIF18B mRNA were detected using real-time fluorescent quantitative PCR in ER+ breast cancer cell lines and clinical specimens of ER+ breast cancer tissue. Two ER+ breast cancer cell lines (YCCB1 and T47D) were transfected with a small interfering RNA targeting KIF18B, and the changes in the proliferative activity and apoptosis of the cells following KIF18B silencing were investigated using a CCK-8 kit and flow cytometry, respectively. Kaplan-Meier analysis was performed to assess the value of KIF18B in evaluating the prognosis of patients with ER+ breast cancer. ResultsKIF18B was highly expressed in ER+ breast cancer cell lines and clinical specimens (P<0.05). KIF18B silencing significantly suppressed the proliferation and enhanced apoptosis of the 2 ER+ breast cancer cell lines (P<0.05). Analysis of Kaplan-Meier showed that ER+ breast cancer patients having a high expression of KIF18B mRNA had poorer overall survival and recurrence-free survival than those with a low KIF18B expression (P<0.05); in the patients receiving tamoxifen therapy, a high expression level of KIF18B mRNA was associated with a poorer distant metastasis-free survival (DMFS) and recurrence-free survival (P<0.05). ConclusionER+ breast cancer expresses high level of kinesin KIF18B, which promotes the proliferation and enhances apoptosis resistance of the tumor cells. A high expression of kinesin KIF18B predicts a poor prognosis of patients with ER+ breast cancer.

参考文献/References:

[1]CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338. 
[2]SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551. 
[3]HARBECK N, GNANT M. Breast cancer[J]. Lancet, 2017, 389(10074): 1134-1150. DOI: 10.1016/s0140-6736(16)31891-8. 
[4]WAKS A G, WINER E P. Breast cancer treatment: A review[J]. JAMA, 2019, 321(3): 288-300. DOI: 10.1001/jama.2018.19323. 
[5]RICHMAN J, DOWSETT M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer[J]. Nat Rev Clin Oncol, 2019, 16(5): 296-311. DOI: 10.1038/s41571-018-0145-5. 
[6]QIAO Y, CHEN J, MA C, et al. Increased KIF15 expression predicts a poor prognosis in patients with lung adenocarcinoma[J]. Cell Physiol Biochem, 2018, 51(1): 1-10. DOI: 10.1159/000495155. 
[7]HAN J, WANG F, LAN Y, et al. KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling[J]. Oncogene, 2019, 38(3): 406-420. DOI: 10.1038/s41388-018-0440-8. 
[8]HOU P F, JIANG T, CHEN F, et al. KIF4A facilitates cell proliferation via induction of p21-mediated cell cycle progression and promotes metastasis in colorectal cancer[J]. Cell Death Dis, 2018, 9(5): 477. DOI: 10.1038/s41419-018-0550-9. 
[9]WANG Y, WU X, DU M, et al. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation[J]. Oncotarget, 2017, 8(26): 42510-42524. DOI: 10.18632/oncotarget.17207. 
[10]ITZEL T, SCHOLZ P, MAASS T, et al. Translating bio-informatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis[J]. Bioinformatics, 2015, 31(2): 216-224. DOI: 10.1093/bioinformatics/btu586. 
[11]WU Y, WANG A, ZHU B, et al. KIF18B promotes tumor progression through activating the  Wnt/β-catenin pathway in cervical cancer[J]. Oncotargets Ther, 2018, 11: 1707-1720. DOI: 10.2147/OTT.S157440. 
[12]KHONGKOW P, GOMES A R, GONG C, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxelresistance[J]. Oncogene, 2016, 35(8): 990-1002. DOI: 10.1038/onc.2015.152. 
[13]ALFARSI L H, ELANSARI R, TOSS M S, et al. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer[J]. Breast Cancer Res Treat, 2019, 173(1): 93-102. DOI: 10.1007/s10549-018-4978-5. 
[14]XUE D, CHENG P, HAN M, et al. An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer[J]. Oncotargets Ther, 2018, 11: 4755-4768. DOI: 10.2147/OTT.S164730. 
[15]WANG C, WANG C, WEI Z, et al. Suppression of motor protein KIF3C expression inhibits tumor growth and metastasis in breast cancer by inhibiting TGF-β signaling[J]. Cancer Lett, 2015, 368(1): 105-114. DOI: 10.1016/j.canlet.2015.07.037. 
[16]LEE Y M, KIM E, PARK M, et al. Cell cycle-regulated expression and subcellular localization of a kinesin-8 member human KIF18B[J]. Gene, 2010, 466(1/2): 16-25. DOI: 10.1016/j.gene.2010.06.007. 
[17]MIKI H, OKADA Y, HIROKAWA N. Analysis of the kinesin superfamily: insights into structure and function[J]. Trends Cell Biol, 2005, 15(9): 467-476. DOI: 10.1016/j.tcb.2005.07.006. 
[18]TANENBAUM M E, MACUREK L, VAN DER VAART B, et al. A complex of Kif18b and MCAK promotes microtubule depolymerization and is negatively regulated by Aurora kinases[J]. Curr Biol, 2011, 21(16): 1356-1365. DOI: 10.1016/j.cub.2011.07.017. 
[19]NUSSE R, CLEVERS H.Wnt/β-catenin signaling, disease, and emerging therapeutic modalities[J]. Cell, 2017, 169(6): 985-999. DOI: 10.1016/j.cell.2017.05.016. 
[20]MCCREA P D, GOTTARDI C J. Beyond β-catenin: prospects for a larger catenin network in the nucleus[J]. Nat Rev Mol Cell Biol, 2016, 17(1): 55-64. DOI:  10.1038/nrm.2015.3. 
[21]HUANG Y, YANG L, PEI Y Y, et al. Overexpressed ACBD3 has prognostic value in human breast cancer and promotes the self-renewal potential of breast cancer cells by activating the Wnt/beta-catenin signaling pathway[J]. Exp Cell Res, 2018, 363(1): 39-47. DOI: 10.1016/j.yexcr.2018.01.003. 
[22]SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimentaldatasets[J]. Nucleic Acids Res, 2019, 47(D1): D607-D613. DOI: 10.1093/nar/gky1131. 
[23]WANG C, WANG W, LIU Y, et al.Rac GTPase activating protein 1 promotes oncogenic progression of epithelial ovarian cancer[J]. Cancer Sci, 2018, 109(1): 84-93. DOI: 10.1111/cas.13434. 
[24]JACOBSEN A, BOSCH L J W, MARTENS-DE KEMP S R, et al. Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer[J]. Sci Rep, 2018, 8(1): 7522. DOI: 10.1038/s41598-018-24982-z. 
[25]瘙塁AHIN S,I瘙塁K GNL I·, AKR A, et al. Clinicopathological significance of the proliferation markers Ki67, RacGAP1, and topoisomerase 2 alpha in breast cancer[J]. Int J Surg Pathol, 2016, 24(7): 607-613. DOI: 10.1177/1066896916653211. 
[26]LAWSON C D, FAN C, MITIN N, et al. Rho GTPase transcriptome analysis reveals oncogenic roles for rho GTPase-activating proteins in basal-like breast cancers[J]. Cancer Res, 2016, 76(13): 3826-3837. DOI: 10.1158/0008-5472.CAN-15-2923. 
[27]GYRFFY B, BENKE Z, LNCZKY A, et al.Recurrence Online: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data[J]. Breast Cancer Res Treat, 2012, 132(3): 1025-1034. DOI: 10.1007/s10549-011-1676-y. 
[28]MIHLY Z, KORMOS M, LNCZKY A, et al. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer[J]. Breast Cancer Res Treat, 2013, 140(2): 219-232. DOI: 10.1007/s10549-013-2622-y. 

相似文献/References:

[1]朱宁生,张婧,曾晓华,等.BMP-4基因影响乳腺癌细胞增殖、凋亡和迁移能力涉及NF-κB途径[J].第三军医大学学报,2012,34(18):1910.
[2]陈显春,杨英,宋爽,等.乳腺癌患者发生化疗性静脉炎的原因分析及防治对策[J].第三军医大学学报,2007,29(21):2055.
[3]张毅,周艳,郭美琴,等.全乳大切片观察新辅助化疗后乳腺癌浸润性生长特征变化[J].第三军医大学学报,2007,29(21):2083.
 ZHANG Yi,ZHOU Yan,GUO Mei-qin,et al.Infiltrating characteristics of breast cancer after neoadjuvant chemotherapy: whole breast serial subsection observation[J].J Third Mil Med Univ,2007,29(18):2083.
[4]陈显春,杨英,宋爽,等.乳腺癌病友联谊会对提高乳腺癌患者生活质量的作用[J].第三军医大学学报,2007,29(20):1967.
[5]邓莉,张轩珍,王卫东,等.重组人内皮抑素联合紫杉醇+顺铂化疗方案治疗人乳腺癌祼鼠移植瘤的研究[J].第三军医大学学报,2008,30(09):783.
 DENG Li,ZHANG Xuan-zhen,WANG Wei-dong,et al.Recombinant human endostatin combined with paclitaxel-cisplatin chemotherapy in treatment of human breast cancer xenograft in nude mice[J].J Third Mil Med Univ,2008,30(18):783.
[6]黄红梅,陈显春.男性乳腺癌患者的心理分析及对策[J].第三军医大学学报,2007,29(23):2222.
[7]杨新华,姜军,范林军,等.乳腺癌腔镜内乳淋巴结清扫的初步研究[J].第三军医大学学报,2007,29(17):1719.
 YANG Xin-hua,JIANG Jun,FAN Lin-jun,et al.Thoracoscopic internal mammary nodes dissection for breast cancer[J].J Third Mil Med Univ,2007,29(18):1719.
[8]廖翠薇,邹利光,戴书华,等.动态增强磁共振成像对乳腺癌的诊断[J].第三军医大学学报,2008,30(16):1516.
 LIAO Cui-wei,ZOU Li-guang,DAI Shu-hua,et al.Diagnosis of breast cancer with dynamic contrast-enhanced magnetic resonance imaging[J].J Third Mil Med Univ,2008,30(18):1516.
[9]张涛,汤为学,蔡辉,等.不同转移潜能乳腺癌细胞亚系的建立与生物学特性的分析[J].第三军医大学学报,2008,30(18):1726.
 ZHANG Tao,TANG Wei-xue,CAI Hui,et al.Establishment of breast cancer cell sublines with different potential of metastasis and their biological characteristics[J].J Third Mil Med Univ,2008,30(18):1726.
[10]李霞,邓华瑜.格尔德霉素对乳腺癌细胞HSP、突变型p53和CDK4表达的影响[J].第三军医大学学报,2007,29(13):1320.
 LI Xia,DENG Hua-yu.Effects of geldanamycin on expression of HSP, mutant p53 and CDK4 in human breast cancer cells[J].J Third Mil Med Univ,2007,29(18):1320.

更新日期/Last Update: 2019-09-21